lapatinib has been researched along with razoxane in 1 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (razoxane) | Trials (razoxane) | Recent Studies (post-2010) (razoxane) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 824 | 115 | 56 |
Protein | Taxonomy | lapatinib (IC50) | razoxane (IC50) |
---|---|---|---|
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.19 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Albini, A; AnzĂ , C; Baravelli, M; Bucci, EO; Cammarota, R; Cesana, E; Donatelli, F; Noonan, DM | 1 |
1 other study(ies) available for lapatinib and razoxane
Article | Year |
---|---|
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heart; Humans; Lapatinib; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Razoxane; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |